Literature DB >> 22440945

Are we ready to recommend aspirin for cancer prevention?

Andrew T Chan1, Nancy R Cook.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22440945      PMCID： PMC3415297          DOI： 10.1016/S0140-6736(11)61654-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  12 in total

1.  Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2007-03-06       Impact factor: 25.391

2.  Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials.

Authors:  Peter M Rothwell; Michelle Wilson; Carl-Eric Elwin; Bo Norrving; Ale Algra; Charles P Warlow; Tom W Meade
Journal:  Lancet       Date:  2010-10-21       Impact factor: 79.321

3.  Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study.

Authors:  T Stürmer; R J Glynn; I M Lee; J E Manson; J E Buring; C H Hennekens
Journal:  Ann Intern Med       Date:  1998-05-01       Impact factor: 25.391

4.  Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial.

Authors:  Nancy R Cook; I-Min Lee; J Michael Gaziano; David Gordon; Paul M Ridker; JoAnn E Manson; Charles H Hennekens; Julie E Buring
Journal:  JAMA       Date:  2005-07-06       Impact factor: 56.272

5.  Long-term use of aspirin and the risk of gastrointestinal bleeding.

Authors:  Edward S Huang; Lisa L Strate; Wendy W Ho; Salina S Lee; Andrew T Chan
Journal:  Am J Med       Date:  2011-05       Impact factor: 4.965

6.  Long-term aspirin use and mortality in women.

Authors:  Andrew T Chan; JoAnn E Manson; Diane Feskanich; Meir J Stampfer; Graham A Colditz; Charles S Fuchs
Journal:  Arch Intern Med       Date:  2007-03-26

7.  Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2009-03-17       Impact factor: 25.391

8.  Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.

Authors:  Bernard F Cole; Richard F Logan; Susan Halabi; Robert Benamouzig; Robert S Sandler; Matthew J Grainge; Stanislas Chaussade; John A Baron
Journal:  J Natl Cancer Inst       Date:  2009-02-10       Impact factor: 13.506

Review 9.  Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials.

Authors:  Peter M Rothwell; Jacqueline F Price; F Gerald R Fowkes; Alberto Zanchetti; Maria Carla Roncaglioni; Gianni Tognoni; Robert Lee; Jill F F Belch; Michelle Wilson; Ziyah Mehta; Tom W Meade
Journal:  Lancet       Date:  2012-03-21       Impact factor: 79.321

10.  Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials.

Authors:  Peter M Rothwell; F Gerald R Fowkes; Jill F F Belch; Hisao Ogawa; Charles P Warlow; Tom W Meade
Journal:  Lancet       Date:  2010-12-06       Impact factor: 79.321
View more
  9 in total

Review 1.  Tumor-associated macrophages: functional diversity, clinical significance, and open questions.

Authors:  Subhra K Biswas; Paola Allavena; Alberto Mantovani
Journal:  Semin Immunopathol       Date:  2013-05-09       Impact factor: 9.623

2.  Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men.

Authors:  Michael Pignone; Stephanie Earnshaw; Cheryl McDade; Mark J Pletcher
Journal:  J Gen Intern Med       Date:  2013-05-17       Impact factor: 5.128

Review 3.  Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention.

Authors:  Farzad Masoudkabir; Nizal Sarrafzadegan; Carolyn Gotay; Andrew Ignaszewski; Andrew D Krahn; Margot K Davis; Christopher Franco; Arya Mani
Journal:  Atherosclerosis       Date:  2017-06-02       Impact factor: 5.162

4.  Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial.

Authors:  Nancy R Cook; I-Min Lee; Shumin M Zhang; M Vinayaga Moorthy; Julie E Buring
Journal:  Ann Intern Med       Date:  2013-07-16       Impact factor: 25.391

Review 5.  Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk.

Authors:  Massimo Volpe; Allegra Battistoni; Giovanna Gallo; Roberta Coluccia; Raffaele De Caterina
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-06-01

6.  The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment.

Authors:  Ronit Vogt Sionov; Zvi G Fridlender; Zvi Granot
Journal:  Cancer Microenviron       Date:  2014-06-04

7.  Low-dose Aspirin, Nonsteroidal Anti-inflammatory Drugs, Selective COX-2 Inhibitors and Breast Cancer Recurrence.

Authors:  Deirdre P Cronin-Fenton; Uffe Heide-Jørgensen; Thomas P Ahern; Timothy L Lash; Peer Christiansen; Bent Ejlertsen; Henrik T Sørensen
Journal:  Epidemiology       Date:  2016-07       Impact factor: 4.822

8.  A short-term risk-benefit analysis of occasional and regular use of low-dose aspirin in primary prevention of vascular diseases: a nationwide population-based study.

Authors:  I-Chen Wu; Hui-Min Hsieh; Ming-Tsang Wu
Journal:  BMJ Open       Date:  2015-01-09       Impact factor: 2.692

9.  A short-term effect of low-dose aspirin on major hemorrhagic risks in primary prevention: a case-crossover design.

Authors:  I-Chen Wu; Ming-Yen Lin; Fang-Jung Yu; Hui-Min Hsieh; Kuei-Fen Chiu; Ming-Tsang Wu
Journal:  PLoS One       Date:  2014-05-30       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.